Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2025 07:00 ET | Source: Upstream Bio

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
February 25, 2025 08:00 ET | Source: Upstream Bio

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio to Present at Upcoming March Investor Conferences
January 06, 2025 08:00 ET | Source: Upstream Bio

Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024 08:00 ET | Source: Upstream Bio

Upstream Bio Appoints Allison Ambrose as General Counsel

Upstream appoints Allison Ambrose as General Counsel
December 16, 2024 08:00 ET | Source: Upstream Bio

Upstream Bio Announces Addition to Russell 2000® Index

Upstream Bio (Nasdaq:UPB) to be added to Russell 2000® index effective at the open of the U.S. equities market on Monday, December 23.
November 21, 2024 08:00 ET | Source: Upstream Bio

Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference

Upstream Bio CEO to participate in fireside chat at Piper Sandler
November 07, 2024 07:00 ET | Source: Upstream Bio

Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Upstream reports third quarter 2024 financial results and recent corporate achievements
October 15, 2024 16:15 ET | Source: Upstream Bio

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Upstream closes $293 million upsized IPO including full exercise of underwriters’ option to purchase additional shares
October 10, 2024 19:35 ET | Source: Upstream Bio

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Upstream Bio announces pricing of upsized initial public offering
October 10, 2022 12:04 ET | Source: AB Science

AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease

PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...

Next Page keyboard_arrow_right